Received: 11 September 2021
Accepted: 3 November 2021
First Online: 4 January 2022
: The study was approved by our institutional review board (Ottawa Health Science Network Research Ethics Board), and all patients provided written informed consent for inclusion and data analysis.
: Not applicable.
: JRI and SBS have nothing to disclose. TDR has research grants from GE HealthCare and Advanced Accelerator Applications. RAD reports grants, consulting fees, and license revenues from Jubilant DraxImage, outside the submitted work. RSBB reports grants and honoraria from Lantheus Medical Imaging, grants and honoraria from Jubilant DraxImage, and grants from GE Healthcare, outside the submitted work. RSBB is a Career Investigator supported but the Heart and Stroke Foundation of Ontario and a Tier 1 Research Chair supported by the University of Ottawa. BJWC receives research support from CV Diagnostix, AusculSciences and Siemens and educational support from TeraRecon Inc. He has equity interest in General Electric. FJR is the Medical Director of Imagia Cybernetics. There is no conflict with respect to this publication. GD provides consultancy support and has equity interest in Artrya Ltd. There is no conflict with respect to this publication.